Solution Phase Libraries by Fluorous Mixture Synthesis

第二阶段SBIR的目标是进行研究和开发，使Fluorous技术公司能够从目前的分析/演示库提升到实际生产库的规模和规模，这将吸引制药和生物技术公司。一旦这种能力到位，FTI打算在组合库合成的外包市场中成为一个高度竞争的参与者。这个市场目前估计2000年将达到1.45亿美元，年增长率为15%。此外，该技术还将商业化用于外部使用。在第一阶段工作成功的基础上，该赠款建议使用该公司创新的新型“含氟混合物合成”平台，以2-3毫克的比例合成4,800-9,600个mappicine类似物成员库。这项工作分为“准备阶段”和“生产阶段”，准备所有需要的起始材料、含氟标签和多样性反应物。在“生产阶段”，将生产、纯化和分析库。建议的商业应用：该研究将在现实环境中验证FTI的含氟混合物合成技术。该公司计划在内部使用这些技术来合成合同库，并将其提供给整个社区。

The goal of the Phase II SBIR is to conduct research and development that will allow Fluorous Technologies, Inc. to ramp up from current analytical/demonstration libraries to the actual production of libraries of a size and scale that will be attractive to pharmaceutical and biotechnology companies. Once this capability is in place, FTI intends to be a highly competitive player in the outsourcing market for combinatorial library synthesis. This market is currently estimated at $145 million for 2000, with an annual growth rate of 15%. In addition, the technology will also be commercialized for external use. Building on successful Phase I work, the grant proposes the synthesis of 4,800-9,600 member library of mappicine analogs on 2-3 mg scale using the company's innovative new "fluorous mixture synthesis" platform. The work is divided into the "preparation phase", where all the needed starting materials, fluorous tags, and diversity reactants will be prepared, and the "production phase", where the library will be produced, purified and analyzed. PROPOSED COMMERCIAL APPLICATION: The research will validate FTI's fluorous mixture synthesis techniques in a real world setting. The company plans to use the techniques in- house for contract library synthesis and to make them available to the community at large.